Cg Oncology Inc (CGON)

$39.82 -0.03 (-0.09%)
Market Cap 3.04B
Revenue (ttm) 1.14M
Net Income (ttm) -88.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,722.81%
Debt to Equity Ratio 0.00
Volume 560,500
Avg Vol 907,738
Day's Range N/A - N/A
Shares Out 76.25M
Stochastic %K 83%
Beta 1.31
Analysts Strong Sell
Price Target $63.82

Company Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC p...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 409 3700
Address:
400 Spectrum Center Drive, Suite 2040, Irvine, United States
highnihilism
highnihilism Oct. 1 at 6:50 AM
$CGON CG Oncology Trade Count: 7 | Total $: 9.3 K | 0.10 × 90-Day Avg $: 96.5 K | Call $: 8.8 K | Put $: 450 | % Single-Leg: 41% | % Multi-Leg: 59% | % Contingent: – $GTX Garrett Motion Trade Count: 24 | Total $: 8.8 K | 0.20 × 90-Day Avg $: 44.8 K | Call $: 8.8 K | Put $: 20 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $TLSA Tiziana Life Sciences Trade Count: 39 | Total $: 9.7 K | 1.41 × 90-Day Avg $: 6.9 K | Call $: 8.8 K | Put $: 915 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $MAGY Roundhill Magnificent Seven Covered Call ETF Trade Count: 6 | Total $: 8.9 K | 2.57 × 90-Day Avg $: 3.4 K | Call $: 8.8 K | Put $: 105 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
TheTinMan
TheTinMan Sep. 23 at 3:00 PM
$TLTFF Rutherin and Ruvidar are miracle compounds, making other compounds even more potent. Acquisition target in the coming 2-3 years, maybe sooner. $CGON $IBRX
0 · Reply
Grinding10
Grinding10 Sep. 22 at 7:36 PM
$CGON guess we r back to the bullshit where it fades everyday again
0 · Reply
TheTinMan
TheTinMan Sep. 22 at 5:22 PM
$TLTFF Rutherrin(R) Shown to Be 100 Times More Effective Than Radiation Alone in Preclinical Cancer Models $CGON $IBRX $MRK $JNJ https://theralase.com/theralase-to-present-groundbreaking-research-at-astro-2025/
2 · Reply
Mik21212
Mik21212 Sep. 19 at 7:30 PM
$CGON
0 · Reply
theflynews
theflynews Sep. 19 at 3:21 PM
Biotech Alert: Searches spiking for these stocks today - $CGON - https://thefly.com/permalinks/entry.php/CGONid4200713?1758294347C38
0 · Reply
Grinding10
Grinding10 Sep. 19 at 2:51 PM
$CGON guess the drug stopped working
0 · Reply
RoundAssRousey
RoundAssRousey Sep. 19 at 1:15 PM
$CGON steadily moving higher. picked this up at $25 on a tip from a buddy. Trial data looks good , price action looks good . Lets keeo it going!
0 · Reply
theflynews
theflynews Sep. 18 at 4:07 PM
Biotech Alert: Searches spiking for these stocks today - $CGON - https://thefly.com/permalinks/entry.php/CGONid4200159?1758211035C38
0 · Reply
Grinding10
Grinding10 Sep. 18 at 8:27 AM
$CGON had a buyout a couple years ago; ISEE 3 months before FDA decision; No rumors no nothing but the stock was moving just like this for 2 weeks; 🤷‍♂️
0 · Reply
Latest News on CGON
CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 10:31 AM EDT - 25 days ago

CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

CG Oncology Stock Signals Bullish Momentum Ahead

Sep 8, 2025, 9:08 AM EDT - 26 days ago

CG Oncology Stock Signals Bullish Momentum Ahead

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

Sep 5, 2025, 7:00 AM EDT - 4 weeks ago

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

CG Oncology Completes Enrollment in PIVOT-006

Sep 3, 2025, 8:00 AM EDT - 4 weeks ago

CG Oncology Completes Enrollment in PIVOT-006

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 8, 2025, 8:00 AM EDT - 2 months ago

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

Jun 23, 2025, 9:58 AM EDT - 3 months ago

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 4 months ago

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

May 13, 2025, 8:00 AM EDT - 5 months ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

Apr 28, 2025, 11:14 AM EDT - 5 months ago

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Apr 26, 2025, 4:10 PM EDT - 5 months ago

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Apr 2, 2025, 12:32 PM EDT - 6 months ago

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Mar 24, 2025, 8:00 AM EDT - 6 months ago

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 7 months ago

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 16, 2024, 4:05 PM EST - 10 months ago

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

Dec 13, 2024, 2:09 PM EST - 10 months ago

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

CG Oncology Announces Pricing of Public Offering

Dec 12, 2024, 8:19 PM EST - 10 months ago

CG Oncology Announces Pricing of Public Offering

CG Oncology Announces Proposed Public Offering

Dec 11, 2024, 6:17 AM EST - 10 months ago

CG Oncology Announces Proposed Public Offering

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

Dec 6, 2024, 1:18 PM EST - 10 months ago

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Dec 6, 2024, 8:00 AM EST - 10 months ago

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Dec 5, 2024, 7:00 AM EST - 10 months ago

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 30, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

CG Oncology: Promising Data, But Looks Expensive

Aug 26, 2024, 10:34 AM EDT - 1 year ago

CG Oncology: Promising Data, But Looks Expensive

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 8, 2024, 8:23 AM EDT - 1 year ago

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

Jul 9, 2024, 9:19 AM EDT - 1 year ago

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

Jun 6, 2024, 12:14 PM EDT - 1 year ago

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 9, 2024, 8:00 AM EDT - 1 year ago

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

May 6, 2024, 1:04 PM EDT - 1 year ago

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

May 3, 2024, 11:23 AM EDT - 1 year ago

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Apr 26, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

Apr 24, 2024, 10:00 AM EDT - 1 year ago

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Mar 28, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Protara: A Bombed Out Biotech With A Very Positive Skew

Feb 22, 2024, 8:55 AM EST - 1 year ago

Protara: A Bombed Out Biotech With A Very Positive Skew

TARA

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 30, 2024, 7:00 AM EST - 1 year ago

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

Jan 29, 2024, 8:14 AM EST - 1 year ago

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

BTSG

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Jan 27, 2024, 1:30 AM EST - 1 year ago

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Biotech's First IPO of 2024 Popped 96%. What It Means.

Jan 26, 2024, 11:50 AM EST - 1 year ago

Biotech's First IPO of 2024 Popped 96%. What It Means.

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

Jan 25, 2024, 2:20 PM EST - 1 year ago

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

CG Oncology valued at $1.75 bln in strong market debut

Jan 25, 2024, 1:46 PM EST - 1 year ago

CG Oncology valued at $1.75 bln in strong market debut

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

Jan 25, 2024, 7:51 AM EST - 1 year ago

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

CG Oncology Announces Pricing of Upsized Initial Public Offering

Jan 24, 2024, 7:10 PM EST - 1 year ago

CG Oncology Announces Pricing of Upsized Initial Public Offering

highnihilism
highnihilism Oct. 1 at 6:50 AM
$CGON CG Oncology Trade Count: 7 | Total $: 9.3 K | 0.10 × 90-Day Avg $: 96.5 K | Call $: 8.8 K | Put $: 450 | % Single-Leg: 41% | % Multi-Leg: 59% | % Contingent: – $GTX Garrett Motion Trade Count: 24 | Total $: 8.8 K | 0.20 × 90-Day Avg $: 44.8 K | Call $: 8.8 K | Put $: 20 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $TLSA Tiziana Life Sciences Trade Count: 39 | Total $: 9.7 K | 1.41 × 90-Day Avg $: 6.9 K | Call $: 8.8 K | Put $: 915 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $MAGY Roundhill Magnificent Seven Covered Call ETF Trade Count: 6 | Total $: 8.9 K | 2.57 × 90-Day Avg $: 3.4 K | Call $: 8.8 K | Put $: 105 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
TheTinMan
TheTinMan Sep. 23 at 3:00 PM
$TLTFF Rutherin and Ruvidar are miracle compounds, making other compounds even more potent. Acquisition target in the coming 2-3 years, maybe sooner. $CGON $IBRX
0 · Reply
Grinding10
Grinding10 Sep. 22 at 7:36 PM
$CGON guess we r back to the bullshit where it fades everyday again
0 · Reply
TheTinMan
TheTinMan Sep. 22 at 5:22 PM
$TLTFF Rutherrin(R) Shown to Be 100 Times More Effective Than Radiation Alone in Preclinical Cancer Models $CGON $IBRX $MRK $JNJ https://theralase.com/theralase-to-present-groundbreaking-research-at-astro-2025/
2 · Reply
Mik21212
Mik21212 Sep. 19 at 7:30 PM
$CGON
0 · Reply
theflynews
theflynews Sep. 19 at 3:21 PM
Biotech Alert: Searches spiking for these stocks today - $CGON - https://thefly.com/permalinks/entry.php/CGONid4200713?1758294347C38
0 · Reply
Grinding10
Grinding10 Sep. 19 at 2:51 PM
$CGON guess the drug stopped working
0 · Reply
RoundAssRousey
RoundAssRousey Sep. 19 at 1:15 PM
$CGON steadily moving higher. picked this up at $25 on a tip from a buddy. Trial data looks good , price action looks good . Lets keeo it going!
0 · Reply
theflynews
theflynews Sep. 18 at 4:07 PM
Biotech Alert: Searches spiking for these stocks today - $CGON - https://thefly.com/permalinks/entry.php/CGONid4200159?1758211035C38
0 · Reply
Grinding10
Grinding10 Sep. 18 at 8:27 AM
$CGON had a buyout a couple years ago; ISEE 3 months before FDA decision; No rumors no nothing but the stock was moving just like this for 2 weeks; 🤷‍♂️
0 · Reply
GMExAPE
GMExAPE Sep. 17 at 10:05 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $LU $CGON $CORT $WGS $KC
0 · Reply
JarvisFlow
JarvisFlow Sep. 17 at 6:00 PM
Morgan Stanley has adjusted their stance on CG Oncology ( $CGON ), setting the rating to Overweight with a target price of 56 → 79.
0 · Reply
theflynews
theflynews Sep. 17 at 3:49 PM
Biotech Alert: Searches spiking for these stocks today - $CGON - https://thefly.com/permalinks/entry.php/CGONid4199421?1758124081C38
0 · Reply
highnihilism
highnihilism Sep. 16 at 6:36 PM
IWM: Russell 2000 → $GEVO Gevo $CGON CG Oncology $KINS Kingstone $PII Polaris $BMBL Bumble
0 · Reply
dlhman2002
dlhman2002 Sep. 16 at 6:34 PM
$CGON Bullish September....
0 · Reply
highnihilism
highnihilism Sep. 16 at 2:56 PM
Biotech → $ARWR Arrowhead Pharmaceuticals $RIGL Rigel Pharmaceuticals $PRAX Praxis Precision Medicines $CGON CG Oncology $ARDX Ardelyx
0 · Reply
JarvisFlow
JarvisFlow Sep. 15 at 12:00 PM
HC Wainwright & Co. has updated their rating for CG Oncology ( $CGON ) to Buy with a price target of 75.
0 · Reply
dtstock1
dtstock1 Sep. 9 at 4:32 PM
$ONCY Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market $HCM $CGON $IDYA $CCCC https://barchart.com/share/news/34665959 via @Barchart
0 · Reply
Main_Street_Risks
Main_Street_Risks Sep. 9 at 1:56 AM
$CGON looking real good. Clearly giving institutional investors confidence with the recent talks. Short term, this is a little stretched for me though. But pivot-6 enrollment was a pleasant surprise. Might even see $45 on this run. Regardless I think this is probably a good multiyear hold from here
0 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 4:26 PM
Jones Trading updates rating for CG Oncology ( $CGON ) to Buy, target set at 50.
0 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 12:00 PM
HC Wainwright & Co. updates rating for CG Oncology ( $CGON ) to Buy, target set at 75.
0 · Reply
RiskCPremium
RiskCPremium Sep. 5 at 7:55 PM
$RLMD After the licensing agreement with Trigone for NDV-01 gel, stock price recovered a bit but still selling at an extremely deep Sergio Traversa/Key-Man/Conman discount. Just look at $CGON today, both are going after the same market but the NDV-01 gel shown much better efficacy so far. He burned and conned not only the shareholders but also analysts from reputable investment banks. That's why current stock price is $1.60 but analysts are keeping their average target price at $1.00. Dr. Raj Pruthi current CMO should lead the company. Trigone & Squadron Capital Management LLC should lead the Board.
1 · Reply